Neurosteer

Neurosteer has developed a solution designed for early detection and more effective treatment of a variety of neurological disorders. Its platform consists of a medical-grade wearable device and a cloud-based system that provide real-time monitoring and assessment of brain activity. The companys current focus is on delivering objective biomarkers to identify the early onset of Parkinsons disease, Alzheimers disease, dementia, and epilepsy. Neurosteer uses an adhesive forehead strip connected to a pocket-sized device that wirelessly transmits sensor data to the cloud for proprietary signal processing. Advanced algorithms then decompose the single EEG channel into over 100 individual components for real-time analysis and display on a web-based dashboard. The results are more affordable screening, continuous patient monitoring, and optimized neurostimulation and drug selection, leading to improved neurological treatment and clinical trial outcomes.

Neurosteer has raised $2.56M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Arkady Volozh.

Neurosteer was founded in 2015 by Prof. Nathan Intrator (Founder).

Neurosteer operates in Health Tech & Life Sciences, Digital Healthcare, Patient Remote Monitoring, Medical Devices, Medical Monitors, Diagnostics Devices, with core technologies in Artificial Intelligence, Machine Learning, Data Storage, Cloud, Semiconductors & Electronics, Wearables, Sensing. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers, Life Sciences, Pharmaceuticals.

Neurosteer is based in Arieh Shenkar St 1, Herzliya, Israel, Center District. The company also has offices abroad.